Skip to main content
Skip to main navigation menu
Skip to site footer
Open Menu
Journal of Commercial Biotechnology
Submissions
Subscribe
Current
Archives
Announcements
Search
About
About the Journal
Editorial Team
Privacy Statement
Contact
Search
Register
Login
Home
/
Archives
/
Vol. 21 No. 3 (2015)
Vol. 21 No. 3 (2015)
Published:
2015-07-01
Commentary
Combating a Global Pandemic of Weak, Adulterated, and Fake Drugs
Menghis Bairu
PDF
The Globetrotting Regulator
Peter J. Pitts
PDF
FDA: Is Off-Label on the Table?
Peter Pitts
PDF
A ‘Genetically Engineered’ Label: Way More Expensive Than You Think
Henry I Miller, Graham Brookes
PDF
Articles
Cannabis-Derived Pharmaceuticals
Clifford S Mintz, Evan Nison, AJ Fabrizio
PDF
Venture Capitalists as gatekeepers for Biotechnological Innovation
Kenneth Fernald, Ruud Hoeben, Eric Claassen
PDF
From the Boardroom
BioTime’s bid to end age-related disease: A look at CEO Michael West’s Vision
Ian C. Clift
PDF
Legal and Regulatory Updates
EU Legal & Regulatory Update – May 2015
Henry Elliott
PDF
Conference Report
Innovation Landscape, Deal-making Strategies and Success Stories
Vasu Pestonjamasp
PDF
Subscription
Login to access subscriber-only resources.
Make a Submission
Make a Submission
Current Issue
